The significance of measuring non-HDL-cholesterol

Preventive Cardiology

Volumn 5, Issue 3, 2002, Pages 156-159

  Hirsch, Glenn A ^a   Vaid, Nidhi ^a   Blumenthal, Roger S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN;

ACCURACY; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG TARGETING; HEALTH EDUCATION; HEALTH PROGRAM; HEART DEATH; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; ADULT; BLOOD; CORONARY ARTERY DISEASE; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0036596229     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2002.00980.x     Document Type: Review

References (25)

1. American Heart Association. Heart and Stroke Facts: 1998 Statistical Supplement. Dallas, TX: American Heart Association; 1997.
2. Armstrong ML, Megan MD. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res. 1972;30:675-680.
3. Harrison DG, Armstrong ML, Freiman PC, et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
4. Havel RJ, Eder H, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
5. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol. 1998;4(suppl A):5A-10A.
6. National Cholesterol Education Program. 2nd Report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
7. Shestor DB, Deer AD, Klimor AN, et al. Increased risk of coronary heart disease death in men with low total and low-density lipoprotein cholesterol in the Austrian lipid research clinics prevalence follow-up study. Circulation. 1993;88:846-853.
8. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
9. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998:1837-1847.
10. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
11. Campos H, Mata L, Siles X, et al. Low-density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187-195.
12. Tornvall P, Karpe F, Carlson LA, et al. Relationships of low-density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 1991;90:67-80.
13. Crouse JR, Parks JS, Schey HM. Studies of low-density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 985;26:566-574.
14. Griffen BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contributions of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241-253.
15. Hardman JG, Gilman AG, Limbird LE, eds. Drugs used in the treatment of hyperlipoproteinemias. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:875-897.
16. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
17. Havel RJ. Postprandial hyperlipidaemia and remnant lipoproteins. Curr Opin Lipidol. 1994;5:102-109.
18. Hamsten A. Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease. Baillieres Clin Endocrinol Metab. 1990;4:895-922.
19. Freidewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-552.
20. Hokanson JE, Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
21. Havel RJ. McCollum Award Lecture, 1993: triglyceride-rich lipoproteins and atherosclerosis - new perspectives. Am J Clin Nutr. 1994;59:795-799.
22. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413-1419.
23. Ballantyne CM, Andrews TC, Hsia JA, et al. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88:265-269.
24. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81(4A):18B-25B.
25. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95(1):69-75.